Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A securities class action has been filed against Capricor Therapeutics (NASDAQ: CAPR) and certain officers over alleged federal securities-law violations during Dec. 17, 2025 to July 26, 2026. The complaint alleges the company adopted changes to the pre-specified statistical analysis plan for Deramiocel without FDA agreement prior to resubmitting its Deramiocel BLA, creating a risk FDA would not find substantial evidence of effectiveness and potentially delaying or denying approval for Duchenne muscular dystrophy. While no financial figures are provided, the litigation risk and disclosure allegations are likely a modest negative for CAPR.

Analysis

This is primarily a credibility event, not a cash-flow event: for pre-commercial biotech, one regulatory-process misstep can re-rate the equity faster than any clinical update because the market is effectively pricing optionality on approval. The biggest near-term loser is CAPR’s equity raise capacity; even before the merits are adjudicated, the overhang can widen bid/ask, raise cost of capital, and make any follow-on financing more dilutive.

Second-order impact is on the “data integrity” discount across small-cap biotech. Names with post hoc statistical adjustments, endpoint ambiguity, or heavy reliance on accelerated approval can see multiple compression over the next 1-3 months as investors demand a larger probability haircut versus the same underlying clinical assets. Larger peers with diversified pipelines should be insulated; the spillover is most acute in single-asset or orphan-DMD names where approval is the entire equity thesis.

The market may be overpricing finality from a complaint alone. The key falsifier is a regulatory or court datapoint that reduces approval risk: FDA confirmation of an acceptable analysis plan, a revised filing accepted without major deficiency, or language suggesting the agency views the totality of evidence favorably. If that happens, the short thesis loses force quickly, and a low-float squeeze is possible because litigation headlines can attract crowded downside positioning.

Key Decisions for Investors

• CAPR: only express downside on strength, not into a panic gap; if borrow is available, use a tactical short or put spread for 1-3 months, covering into any FDA clarification or court hearing date.
• CAPR: if options liquidity exists, favor defined-risk bearish structures over outright shorting because litigation headlines can create sharp squeeze risk in microcap biotech.
• XBI / IBB: monitor for sector read-through rather than take a broad biotech hedge immediately; this is more likely to pressure sub-$1B, single-asset names than the index.
• No trade on FCD.UN.TO from this item; there is no visible transmission channel and forcing a position would be unsupported.